About SpringWorks Therapeutics
SpringWorks Therapeutics is a company based in New York (United States) founded in 2017 was acquired by Merck in April 2025. SpringWorks Therapeutics has raised $229.6 million across 4 funding rounds from investors including Pfizer, Merck and Citadel. SpringWorks Therapeutics offers products and services including Nirogacestat and Mirdametinib. SpringWorks Therapeutics operates in a competitive market with competitors including QSAM Biosciences, Vuja De Sciences, ECM Therapeutics, Atlanthera and Taithera, among others.
- Headquarter New York, United States
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Springworks Therapeutics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SpringWorks Therapeutics
SpringWorks Therapeutics offers a comprehensive portfolio of products and services, including Nirogacestat and Mirdametinib.
Gamma secretase inhibitor for BCMA combinations in multiple myeloma.
Treatment for NF1-PN in pediatric and adult patients.
People of SpringWorks Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
28 people
Software Development Team
28 people
Sales and Marketing
14 people
Operations Team
12 people
Human Resources and Administration
5 people
Finance and Accounting
4 people
Legal and Compliance
4 people
Senior Team
3 people
Unlock access to complete
Funding Insights of SpringWorks Therapeutics
SpringWorks Therapeutics has successfully raised a total of $229.6M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $225 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SpringWorks Therapeutics
SpringWorks Therapeutics has secured backing from 18 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Merck and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked |
Investor details for SpringWorks Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SpringWorks Therapeutics
Investment portfolio details for SpringWorks Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SpringWorks Therapeutics
Detailed financials for SpringWorks Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Springworks Therapeutics Comparisons
Peer comparison for SpringWorks Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SpringWorks Therapeutics
SpringWorks Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as QSAM Biosciences, Vuja De Sciences, ECM Therapeutics, Atlanthera and Taithera, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of nuclear medicines for the treatment of bone cancer treatment & bone marrow ablation
|
|
| Locked | Locked | Locked |
Therapies for preventing cancer metastasis and recurrence are developed.
|
|
| Locked | Locked | Locked |
Diagnostic and therapeutic products from extracellular matrix are developed.
|
|
| Locked | Locked | Locked |
Small molecule drugs for bone diseases and tumors are developed.
|
|
| Locked | Locked | Locked |
Nanomedicine platform for targeted bone drug delivery is developed.
|
Detailed competitors of SpringWorks Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Springworks Therapeutics
Complete news archive for SpringWorks Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SpringWorks Therapeutics
SpringWorks Therapeutics was founded in 2017.
SpringWorks Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Saqib Islam is the current CEO of SpringWorks Therapeutics.
SpringWorks Therapeutics is a funded company, having raised a total of $229.6M across 4 funding rounds to date.
Founded in 2017 and based in New York, United States, small molecule therapeutics are developed by SpringWorks Therapeutics within the biotechnology sector for cancer and rare diseases. Operations focus on advancing candidates such as Nirogacestat, a gamma-secretase inhibitor targeting desmoid tumors, a MEK 12 inhibitor for neurofibromatosis type 1, and senicapoc for hereditary xerocytosis involving dehydrated red blood cells.
SpringWorks Therapeutics's top competitors include Vuja De Sciences, QSAM Biosciences and Taithera.
SpringWorks Therapeutics offers Nirogacestat and Mirdametinib.